Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The Evolving Management of Relapsed/Refractory Myeloma: Clinical, Economic, and Patient-Centric Strategies for Managed Care Pharmacy Professionals

Credits Available
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: June 15, 2022 Expiration: June 14, 2023
Start Activity
Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
Bristol-Myers Squibb
Karyopharm Therapeutics Inc.
Rebecca Gonzalez, PharmD, BCOP
Bhavesh Shah, RPh, BCOP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recognize approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to aid the interprofessional, collaborative care team in treatment decision making using available data and patient-related and disease-related factors
  • Develop an understanding of the mechanisms of action of and clinical trial findings with recently FDA-approved novel therapies to facilitate optimal integration into treatment algorithms/clinical pathways
  • Assist the interprofessional, collaborative care team in the supportive care of patients with relapsed/refractory multiple myeloma through early detection and management of treatment-related adverse events
  • Identify ways managed care pharmacists can promote optimal clinical integration of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to reduce associated costs, decrease hospitalization, and improve outcomes for patients

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Rebecca Gonzalez, PharmD, BCOP, has no relevant conflicts of interest to disclose.
Bhavesh Shah, RPh, BCOP

Chief Pharmacy Officer
Department of Pharmacy
Boston Medical Center Health System
Boston, Massachusetts

Bhavesh Shah, RPh, BCOP, has disclosed that he has received funds for research support and consulting fees from Fujifilm, Incyte, Janssen, Novartis, Pfizer Rigel, and Sanofi.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jamie Sebaaly

Director, Educational Strategy

Jamielynn Sebaaly, PharmD, BCPS, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Brian Purves
Brian Purves has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with relapsed/refractory multiple myeloma as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with relapsed/refractory multiple myeloma.

Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-095-H01-P has been assigned to this home study, application-based activity (initial release date 3-31-2022). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 15, 2022, through June 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

The Evolving Management of Relapsed/Refractory Myeloma: Clinical, Economic, and Patient-Centric Strategies for Managed Care Pharmacy Professionals

Loading...
In this on-demand webcast of a live symposium, expert faculty discuss the management of relapsed/refractory multiple myeloma, including considerations for managed care professionals.
Rebecca Gonzalez, PharmD, BCOP
Bhavesh Shah, RPh, BCOP
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: June 15, 2022 Expiration: June 14, 2023

Related Content

Pharmacists review the latest findings in the treatment of relapsed/refractory multiple myeloma and provide clinical insights based on their personal experiences, from Clinical Care Options (CCO).

Rebecca Gonzalez, PharmD, BCOP Donald C. Moore, PharmD, BCPS, BCOP, DPLA Released: July 29, 2022

Downloadable slideset on advances in relapsed/refractory multiple myeloma, from ProCE, LLC in partnership with Clinical Care Options (CCO).

Rebecca Gonzalez, PharmD, BCOP Donald C. Moore, PharmD, BCPS, BCOP, DPLA Released: July 7, 2022

Rebecca Gonzalez, PharmD, BCOP, discusses key pharmacy strategies for management of patients with multiple myeloma in this commentary from Clinical Care Options (CCO)

Rebecca Gonzalez, PharmD, BCOP Released: May 6, 2022

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023
Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
Bristol-Myers Squibb
Karyopharm Therapeutics Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings